Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00739661 | A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission | completed | Phase 2 | 104 | Genentech, Inc.INDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT01462149 | Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer | completed | Phase 2 | 43 | Asan Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00376987 | Zinc Supplements in Lowering Cadmium Levels in Smokers | completed | Phase 2 | 61 | Wake Forest University Health SciencesOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00534001 | Bupropion in Helping Adults Stop Smoking | completed | Phase 2 | 95 | Roswell Park Cancer InstituteOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01175343 | RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00097019 | A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed | completed | Phase 2 | 53 | Genentech, Inc.INDUSTRY | 0 | May 16, 2017 | clinicaltrials |
| NCT00780039 | A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) | completed | Phase 2 | 58 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT01068509 | Ovarian Cancer Vaccine for Patients in Remission | completed | Phase 2 | 63 | Prima BioMed LtdINDUSTRY | 2 | May 11, 2017 | clinicaltrials |
| NCT01276548 | A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer(GPMOC202) | completed | Phase 2 | 102 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | May 9, 2017 | clinicaltrials |
| NCT00157573 | GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer | completed | Phase 2 | 72 | Massachusetts General HospitalOTHER | 0 | May 8, 2017 | clinicaltrials |
| NCT00879359 | Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer | completed | Phase 2 | 15 | The Cleveland ClinicOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01306032 | Phase II ABT-888 With Cyclophosphamide | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 2 | Apr 26, 2017 | clinicaltrials |
| NCT00545792 | Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | completed | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00957905 | Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00321932 | Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | University of MinnesotaOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00058552 | A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer | completed | Phase 2 | 129 | Genentech, Inc.INDUSTRY | 0 | Mar 8, 2017 | clinicaltrials |
| NCT00523380 | Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer | completed | Phase 2 | 10 | Novo Nordisk A/SINDUSTRY | 2 | Mar 1, 2017 | clinicaltrials |
| NCT00002931 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer | completed | Phase 2 | 48 | City of Hope Medical CenterOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00158379 | Taxol Carboplatin and Erythropoetin | completed | Phase 2 | 105 | North Eastern German Society of Gynaecological OncologyOTHER | 0 | Feb 6, 2017 | clinicaltrials |
| NCT00584857 | A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer | completed | Phase 2 | 30 | University of Alabama at BirminghamOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT02199418 | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer(SHPD001) | completed | Phase 2 | 132 | RenJi HospitalOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT00003657 | High-dose ICE With Amifostine | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00073541 | A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer | completed | Phase 2 | 38 | EMD SeronoINDUSTRY | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00559377 | FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2016 | clinicaltrials |
| NCT00872989 | S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 129 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 19, 2016 | clinicaltrials |
| NCT01669226 | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer(AICE) | completed | Phase 2 | 215 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00031629 | Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00314678 | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer | completed | Phase 2 | 40 | John P. FruehaufOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT00179712 | Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | completed | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT00171808 | Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer(deFEND) | completed | Phase 2 | 26 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT00744718 | Bevacizumab and Carboplatin for Patients With Ovarian Cancer | completed | Phase 2 | 73 | Vejle HospitalOTHER | 1 | Nov 16, 2016 | clinicaltrials |
| NCT02017353 | Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma | completed | Phase 2 | 7 | University Hospital, GasthuisbergOTHER | 1 | Oct 25, 2016 | clinicaltrials |
| NCT02562729 | Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer | completed | Phase 2 | 62 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Oct 14, 2016 | clinicaltrials |
| NCT01630018 | Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial | completed | Phase 2 | 141 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Sep 22, 2016 | clinicaltrials |
| NCT00112086 | OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 | completed | Phase 2 | 56 | Japan Clinical Oncology GroupOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01031381 | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer(RADBEV) | completed | Phase 2 | 50 | University of PittsburghOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT02523365 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT00710762 | A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer | completed | Phase 2 | 89 | Boehringer IngelheimINDUSTRY | 1 | Aug 15, 2016 | clinicaltrials |
| NCT01022346 | A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection | completed | Phase 2 | 206 | Hoffmann-La RocheINDUSTRY | 6 | Aug 15, 2016 | clinicaltrials |
| NCT01246440 | Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission | completed | Phase 2 | 39 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Aug 11, 2016 | clinicaltrials |
| NCT01455493 | A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma | completed | Phase 2 | 56 | Genentech, Inc.INDUSTRY | 1 | Aug 11, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT01639625 | Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application | completed | Phase 2 | 18 | Laboratorio Elea Phoenix S.A.INDUSTRY | 1 | Aug 2, 2016 | clinicaltrials |
| NCT00091377 | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 65 | MEI Pharma, Inc.INDUSTRY | 2 | Jul 14, 2016 | clinicaltrials |
| NCT00031759 | Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia | completed | Phase 2 | 57 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT01283035 | A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2016 | clinicaltrials |
| NCT00327171 | Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer | completed | Phase 2 | 218 | SanofiINDUSTRY | 11 | Jun 7, 2016 | clinicaltrials |
| NCT01013324 | Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma | completed | Phase 2 | 67 | SanofiINDUSTRY | 2 | Jun 3, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2017source: clinicaltrials